Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TML-6 in Early Alzheimer's Disease
NCT07612150Phase 2Not yet recruiting
- Sponsor
- Merry Life Biomedical Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Apr 2028
01
Overview
Phase 2, randomised, double-blind trial of TML-6 in Alzheimer's disease (AD) (3 arms), sponsored by Merry Life Biomedical Co., Ltd. Primary endpoint: Clinical Dementia Rating - Sum of Boxes at 52 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
TML-6
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07612150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612150.